Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

In a little over two decades, almost 260 million people in the United States are predicted to have overweight or obesity, ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...

DaVita’s strong services face risks from debt and economic uncertainties. Find out why DVA stock is a "Hold" with a $130 ...

In an essay for 'Women's Health,' Dr. Nora Volkow discusses the future of semaglutide weight-loss meds, and their potential ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associ ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...